PT  - JOURNAL ARTICLE
AU  - Lederman, Lynne
ED  - Chey, William D.
TI  - Eluxadoline Shows Efficacy for IBS-D in IBS3001 and IBS3002 Phase 3 Trials
DP  - 2015 Sep 07
TA  - MD Conference Express
PG  - 12--13
VI  - 15
IP  - 14
4099  - http://mdc.sagepub.com/content/15/14/12.2.short
4100  - http://mdc.sagepub.com/content/15/14/12.2.full
AB  - Eluxadoline, a µ-opioid receptor agonist and d-opioid receptor antagonist, exhibits rapid onset of action along with sustained efficacy over the 6-month treatment period as studied in the phase 3, double-blind, placebo-controlled IBS3001 and IBS3002 trials in patients with diarrhea-predominant irritable bowel syndrome.